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summarizes the resistance mechanisms that NTM organisms adopt to evade attack from conventional antibiotic agents.
Given that the NTM organisms are environmental, it is not surprising that they have developed highly elaborate mechanisms of AMR. The environment, particularly the rhizosphere, is a harsh environment for NTMs to survive, due to highly complex inter-strain, inter-species, and inter-genus competition for habitat and nutrition. Therefore, it is advantageous that any organism can ideally perform two important functions in such a scenario, namely (i). evolve AMR mechanisms to evade natural antibiotics being excreted as secondary metabolites by neighboring bacteria, as well as (ii) having the ability to excrete novel natural antibiotic and/or antibiotic-like compounds, to suppress the growth and proliferation of neighbor bacterial organisms. While the NTMs are highly evolved in relation to developing AMR mechanisms, their ability to produce novel antimicrobial compounds is limited whereas paradoxically, another soil organisms, Streptomyces spp., are highly developed in producing novel antimicrobial compounds, but lack sophisticated AMR mechanisms, to evade natural antimicrobials from their neighbors in the soil.
mechanIsms to combat antImIcrobIal resIstance In nontuberculous mycobacterIa
The aim of this review is to highlight recent developments which have appeared in the scientific literature within the last 2 years (2017-2018), examining a variety of approaches targeting NTMs. [7] [8] [9] [10] Medicinal plants are a source of bioactive compounds that can be effective treatments of various diseases globally. Many countries, particularly Mexico, India, Iran, Turkey, and Africa, have a wealth of medicinal plant species which have had a long standing in traditional medicine approaches to the treatment and management of diseases including tuberculosis. [11] Ethnobotanical/pharmacological studies relating of the use of such plants in conjunction with polyherbal medicines, [12] traditionally used for the treatment of tuberculosis are forming the foundations for [7] [8] [9] [10] the identification and in vitro examination of antibacterial properties against NTMs [ Table 2 ].
Animal venoms from snakes (terrestrial and sea), scorpions, spiders, honey bees, wasps, and snails, have been investigated and found to be a rich source of natural antimicrobial substances including proteins, amines, bioactive peptides, antimicrobial peptide (AMP), toxins and enzymes, showing activity, by a number of different mechanisms, against many pathogens and more recently, NTMs [ Table 3 ]. [30] Of particular, clinical interest has been the AMPS which are short (10-15 amino acid residues), due to the fact that they are structurally stable, do not easily induce AMR compared to conventional antimicrobials and have shown potent potential in killing bacteria, fungi, viruses, and parasites. AMPs are currently a source of therapeutic potential particularly as they are devoid of hemolytic properties, not toxic to host cells and may be readily synthesized and modified. [30] Owing to the intrinsic resistance of NTMs to most commonly used antibiotics, such infections are treated by a multidrug regimen as highlighted in the recent "British Thoracic Society Guidelines for the management of non-tuberculous mycobacterial pulmonary disease," [36] however, treatment issues are further complicated by the ability of Mycobacterium abscessus to develop macrolide resistance on exposure to sub-inhibitory concentrations of the drug [36] or where other members of the macrolides are used, such as in the case of low-dose azithromycin in the management of patients with cystic fibrosis (CF). Currently, screening for synergistic interactions of approved drugs is an approach which has identified novel in vitro synergistic combinations, with one of the largest studies totaling 180 dual drug combinations against M. abscessus, reported recently by Aziz et al. 2018 . [37] Table 4 summarize several studies which report on potential synergistic and combination effects with other antimicrobials.
Of interest, has been a recent publication examining the interaction between spices and antibiotic resistance in M. abscessus. [48] In this study, M. abscessus isolates (n = 9 multidrug-resistant clinical isolates from CF patients + 1 reference strain) were examined for their direct susceptibility to 27 spices, as well as the interactive effect of this spice combination to their susceptibility to amikacin and linezolid antibiotic, with standard disk diffusion assay. Five isolates of M. abscessus (5/10; 50%) failed to grow on the spice enriched medium, which included four clinical isolates and the National Culture Type CollectionReference Strain. Of the remaining five isolates which grew on the spice medium, no cultural phenotypic differences were observed, compared to unsupplemented controls. In the case of both amikacin and linezolid, the zone of inhibition increased with the inclusion of the spices. Initially, all isolates of M. abscessus were fully resistant to linezolid (mean zone of inhibition = 0 mm), and growth was to the edge of the antibiotic disk, whereas when in the presence of spices, large zones of inhibition were observed (mean zone of inhibition = 33.3 mm). With amikacin, the mean zone of inhibition increased from 23.2 mm to 32.0 mm, in the presence of spices. These data suggest that the spices were interacting synergistically with the antibiotics, thus making the antibiotic more potent against the bacteria tested. This study is significant as it demonstrates a positive interaction between spices and the conventional antimycobacterial antibiotics, amikacin, and linezolid. Given the burden of AMR to M. abscessus, particularly in a patient with chronic disease such as CF, any food-related innovation that can help maximize the potency of existing antimycobacterial antibiotics is to be encouraged and developed. The specific mechanism as to how spices increase the potency of such antibiotics with M. abscessus now needs to be elucidated, as well as novel food (spice) delivery modalities developed, including novel medicinal foodstuffs or functional foods, that can harness this beneficial effect in vivo.
Due to the urgent need to address the AMR of NTMs, it is important to discover new antimycobacterials, however to date, such drug discovery has been limited, particularly in relation to progression of such novel drugs to clinical trials [ Table 5 ]. [10] Of particular, interest has been the development of a novel inhaled nonantibiotic therapy, nitric oxide gas formulation, Thiolanox ® (Novoteris, Garden Grove, CA., USA), for the treatment of CF and which is currently in Phase II development (NCT02498535). Interestingly, in Phase I of the clinical study, with CF patients, 160ppm NO inhaled for 30 min, three times daily for five days over two consecutive weeks, indicated that this therapy was safe and significantly reduced the number of various bacteria including M. abscessus, which consequently reduced pulmonary inflammation and increased lung function to levels not commonly observed after antibiotic therapy [76] [ Table 6 ]. It has been suggested that NO has a multiplicity of targets that are non-organism specific, attributed to its oxidative and nitrosylating effects. NO eradicates microbes by nitrosylating their heme-or thiol-containing essential metabolic proteins which interfere with RNA replication and DNA repair mechanisms, which in turn damages cellular structure and function and modulates the host immune response. [76] Subsequently, an interventional clinical trial is currently in progress to investigate if NO therapy can reduce the NTM bacterial load in the lungs of adults and adolescents with NTM infection (NCT03331445), the preliminary results of which are summarized in Table 6 . Furthermore, the antibacterial efficacy of a biopolymer, NO-donor BIOC51 (Vast Therapeutics, Chapel Hill, NC., USA) has been demonstrated against NTMs in a mouse in vitro and in vivo model. [66] It is important to consider the fact that NTM can exist both extracellularly in biofilms and intracellularly within macrophages and other host cells, where they can replicate intracellularly. This promotes a challenge when delivering antimicrobial therapy at concentrations which would be effective against NTMs persisting either within biofilms or intracellularly within host cells. Of significant interest has been the development of a liposomal amikacin formulation Contd... [13] MICs of the EOs against the mycobacteria (39- [14] Hexane, CH 2 Cl 2 , EtOAc, and ethanolic extracts had antibacterial activity against M. tuberculosis H37Rv Ethanol extract subjected to fractionation by selective extractions, purified compound of phenolic nature obtained (MIC; 3.125 μg/ml against M. tuberculosis) Hexane and dichloromethane extracts were effective against M. smegmatis Aqueous crude extract did not display antimycobacterial activity, but following fractionation, isolation of 3,5-hydroxybenzoic acid, showed biological activity against M. tuberculosis
Medicinal herbal plants (Senegal) (Combretum aculeatum and Guiera senegalensis) [15] Aqueous extracts demonstrated significant antimycobacterial activities IC 50 -G. senegalensis (0.098±0.009 mg/ml) and C. aculeatum (0.074±0.006 mg/ml), compared to Rifampin (0.007±0.0004 mg/ml)
M. marinum
Medicinal plants (Datura stramonium, Boswellia serrata, Lavandula stoechas, Rosmarinus officinalis, Thymus vulgaris) [16] Crude ethanol extract showed antimycobacterial activity (MIC: 125-500 μg/ml) L. stoechas and D. stramonium in combination with ethambutol, the FICI was 0.125 μg/ml for both Synergistic effects with isoniazid and ethambutol
M. bovis
Combined crude extracts of medicinal plants (Limpopo Province, South Africa) Combretum heroroense, Citrus lemon Apodytes dimidiate [17] MICs; crude extracts (0.1-3 mg/ml), average synergistic effect of the plants (0.04 mg/ml-1.25 mg/ml) Hexane and butanol sub-fractions of A. dimidiata exhibited potent anti-mycobacteria activity
M. smegmatis
Alkaloid extracts from Combretum zeyheri [18] MIC value of 125 μg/ml Other Combretum species examined were not as potent
Curcumin, a phenolic compound extracted from Curcuma longa [19] MIC=128 mg/L Synergic effect of curcumin with AMK, clarithromycin, ciprofloxacin and LZD (strain initially showed resistance/intermediate susceptibility)
Curcumin (1/8×MIC) significantly reduced motility and 4 × MIC, complete inhibition of 4-and 8-day mature biofilms Synergistic combinations of curcumin and AMK induced a reduction in microbial aggregates and substantial loss in cell viability
M. abscessus
Nanoemulsions of Cymbopogon flexuosus [20] Nanoemulsion exhibited significant antimicrobial activity with MICs lower than those of the free EO, against strains in the planktonic state M. fortuitum M. massiliense M. abscessus Phytochemicals from Parinari curatellifolia leaf extracts [21] MICs; 6.2 μg/ml for the acetone extract, 12.5 μg/ml for both the ethanol and the total extract and 50 μg/ml for both the methanol and ethyl acetate extracts Ethanol extract with kanamycin enhanced the inhibition of biofilm formation
M. smegmatis
Stem bark of Tetracera potatoria Afzel. Exg. Don (Dilleniaceae) medicinal plant used traditionally in Africa [22] Tetraceranoate exhibited the best activity against M. smegmatis with a minimum MIC of 7.8 µg/mL β-stigmasterol, betulinic acid and betulin showed appreciable anti-mycobacterial activity against both strains (MIC 15 µg/mL)
M. smegmatis M. aurum
Persimmon (Ebenaceae Diospyros kaki Thunb.) derived tannin [23] Soluble tannin hydrolysate exhibited high bacteriostatic activity against MAC in vitro MAC infected mice fed a soluble tannin-containing diet showed significantly higher anti-bacterial activity against MAC than control fed animals Levels of pro-inflammatory cytokines and iNOS were significantly reduced by treatment with soluble tannin hydrolysate MAC Rhynchosia precatoria (Humb. and Bonpl. ex Willd.) (Fabaceae) DC. Medicinal plant [24] New isoflavanones identified Antimycobacterial and synengistic antimycobacterial activiy noted M. tuberculosis M. smegmatis to address these issues and in particular liposomal inhalation suspension which can be delivered by to target NTM lung diseases. Such delivery mechanisms ensure the delivery of high concentrations of antibiotic directly to the lung along with low systemic concentration in an attempt to prevent cytotoxicity. [81] In vitro and in vivo animal models have shown the ability which this liposomal inhalation suspension has in penetrating NTM biofilms, as well as enhancing amikacin uptake into macrophages. [81] Of major clinical interest has been a multi-centered clinical trial (NCT02344004) which concluded that a single daily nebulization of amikacin liposome inhalation suspension (590 mg), when added to standard guideline-based therapy (GBT) in patients with refractory Mycobacterium avium complex (MAC) lung disease, achieved significantly greater culture conversion by month 6 (defined as three MAC-negative sputum cultures) than GBT alone, along with comparable rates of serious adverse events. [82] These findings further highlight the importance of novel inhaled therapeutic approaches for the treatment of MAC lung disease.
Another approach to tackle the challenge posed by NTM AMR has been the repurposing of existing drugs, namely those that had been approved previously for the treatment of tuberculosis, such as bedaquiline, clofazimine, rifabutin and skin infections, such as tedizolid [ Table 7 ]. Of concern, however, is that fact the resistance mechanisms associated with the MmpL family of proteins have been identified in M. abscessus, in the case of clofazimine and bedaquiline, where clofazimine-resistant strains demonstrated cross resistance to bedaquiline. [90, 91, 97] In addition, in vitro, the antimicrobial effect on NTMs as a result of polypharmacy for the treatment of noninfective conditions has been noted and opens up another avenue to peruse [ Table 7 ]. Table 8 highlights a number of other approaches which have been investigated in the search for antimycobacterial drugs for NTMs including the examination of existing screening libraries and the examination of bacterial virulence and pathogenic mechanisms with the potential to develop antivirulence therapies and bacteriophage therapy.
Bacteriophage therapy is an interesting approach to consider in the fight against AMR, however to date research in the potential use of such therapy in the case of NTM has been limited with recent focus associated with M. tuberculosis. [105] Indeed, phage therapy although extensively used in Eastern Europe in relation [26] Organic mycelial extracts of Lentinus and Pleurotus species exhibited potential antibacterial and antifungal activity
M. smegmatis

Marine sources
Bioactive Pyridone Alkaloids from Deep-Sea-Derived Fungus Arthrinium spp. UJNMF000 [27] Eight new 4-hydroxy-2-pyridone alkaloids arthpyrones and two known analogs (apiosporamide and arthpyrone B) were studied IC 50 values ranged from 1.66 to 42.8 μM
M. smegmatis
Dimeric 3-alkyl pyridinium alkaloids (haliclocyclamines) and analogs (cyclostellettamines) from Indonesian marine sponge Haliclona spp. [28] Anti-mycobacterial activity noted M. smegmatis
Bisfunctionalized sphingolipid (leucettamol A) from Indonesian marine sponge Agelas spp. [29] Leucettamol A-moderate anti-mycobacterial activity (50 µg/disk, 20 µg/disk and 10 µg/disk inhibition zones: 12, 9 and 7 mm, respectively) Free amino groups were important for anti-mycobacterial activity [31] ToAP2 inhibited the growth of M. massiliense at a MBC of 200 μM MBC concentration used to treat infected macrophages was able to inhibit 50% of the bacterial growth of all strains ToAP2 treatment of infected mice with bacilli reduced the bacterial load in the liver, lung, and spleen, similar to clarithromycin levels (90%) The in vitro antimicrobial activity of ToAP2 is improved in vivo due to chemotactic activity M. massiliense NDBP-5.5 (derived from scorpion Hadrurus gertschi) [32] MBC 200 μM which did not induce hemolysis of red blood cells NDBP-5.5 had a low toxicity and therefore good clinical potential (therapeutic index 3.05) Treatment of infected macrophages with NDBP-5.5 or clarithromycin presented similar results, reducing the bacterial load M. abscessus subsp. massiliense-infected animals showed a decrease in the bacterial load of up to 70% when treated with NDBP-5.5
M. abscessus subsp. massiliense
AMPs developed from CTX-1 of the Chinese cobra (Naja atra) [33] Potent antimicrobial activity was demonstrated M. smegmatis M. fortuitum Polybia-MPII, a mastoparan peptide from the female Neotropical social wasp Pseudopolybia vespiceps testacea (Vespidae, Hymenoptera) [34] The mastoparan reduced in vitro and ex vivo (macrophage murine model) mycobacterial growth by 80% at 12.5 μM in infected peritoneal macrophages but did not affect the shape of bacterial cells at the dose tested (6.25 μM) Polybia-MPII as a therapeutic alternative demonstrated remarkable potential to inhibit mycobacteria and to penetrate the cell wall to kill bacteria from inside the cytoplasm
M. abscessus subsp. massiliense
Polydim-I, from the female Neotropical wasp Polybia dimorpha [35] Polydim-I iv. treatment of with M. abscessus subspp. massiliense [38] In vitro activity of several antibiotics against a selection of drug-resistant NTM clinical isolates from CF patients and paired combinations of antibiotics against a subset of M. abscessus strains Clofazimine and clarithromycin exhibited 100% synergy for all combinations tested, as did AMK, with the exception of one isolate M. abscessus M. chelonae MAC Synergistic effect of LZD with AMK, MOX, CFX and TGC [39] LZD and AMK most potent synergistic activity Frequent synergism in LZD-AMK and LZD-TGC LZD rarely exhibited in vitro synergy with MOX and CFX when tested against MABC LZD-CFX and LZD-MOX combinations antagonistic for half of the isolates
M. abscessus M. massiliense
Clarithromycin-vancomycin [40] Strong synergy was found with a FICI score of≤0.5 and a 4-to10-fold decrease in MIC MABSC (subspecies) abscessus, bolletii, massiliense Thioridazine/MOX -based combination regimen [41] Rapid microbial kill could be achieved within 7 days M. avium-intracellulare complex Ceftazidime/avibactam, rifabutin, TZD and MOX [42] Kill rates better than standard therapy M. avium subspp. hominissuis Ceftazidime/avibactam [43] Ceftazidime in combination with the non-β-lactam β-lactamase inhibitor avibactam kills MAC Microbial kill was better than that of standard therapy drugs at currently recommended doses MAC 
Combinations
Study findings Species used
Avibactam and various carbapenems [44] The addition of avibactam to various carbapenem antibiotics effectively reduced the MICs of carbapenem-resistant M. abscessus isolates to within therapeutically achievable levels in vitro M. abscessus Clarithromycin, rifampin, rifabutin, and ethambutol in combination with ATP [45] In vitro anti-Mycobacterium complex activity of combination therapies was expressed in a strain-dependent manner In vitro regrowth of drug-treated bacteria was delayed by combined use of ATP MAC Synergistic effect of Clarithromycin with LZD, MOX , AMK, and tigecycline [46] In vitro, synergistic activity was noted with clarithromycin and various other drugs M. abscessus M. massiliense Rifampicin with hydroperoxides [47] Increased membrane permeability owing to the presence of the oxidant, led to higher uptake of the drug Additive effect was noted M. bovis M. smegmatis M. tuberculosis Interaction of South Asian spices with conventional antibiotics [48] Synergetic antimicrobial activity noted in vitro between spice extracts and AMK and LZD
M. abscessus
Teicoplanin -Tigecycline combination [37] In vitro checkerboard titration assay TZD, a next-generation oxazolidinone [55] In vitro kill time analysis using 130 isolates TZD exhibited a bacteriostatic effect that was more pronounced in M. [56] TZD was associated with extensive microbial kill of MAC Susceptibility breakpoint for TZD (200 mg/day) was 1 mg/L, above which patients were likely to fail therapy; 2 mg/L was a susceptible-dose-dependent breakpoint
M. avium subspp. hominissuis
Inhibitors Against Mycobacterial Protein Kinase G (PknG) [57] PknG is a eukaryotic-like serine/threonine kinase that is expressed by Mycobacterium tuberculosis and promotes survival of mycobacteria in host macrophages by suppressing phagosome-lysosome fusion PknG inhibitors identified
M. bovis
Novel Oxazolidinone with a cyclic amidrazone (LCB01-0371, LegoChem BioSciences, Inc. (Daejeon, Republic of Korea) [58] LCB01-0371 was effective against several M. abscessus strains in vitro and in a macrophage model of infection LCB01-0371 inhibited the growth of AMK-, CFX -and clarithromycin-resistant strains
M. abscessus
LZD, 50S ribosome target [59] The clinical dose of 600 mg/day achieved or exceeded the bacteriostasis exposure in 98.73% of patients The proportion of 10000 patients Monte Carlo simulations treated with the standard 1200 mg/day who achieved the exposure for 1.0 log10 cfu/mL kill was 70.64%, and 90% for 1800 mg/day MIC for the laboratory strain was 4.0 mg/L The proposed MIC breakpoint for LZD is 16 mg/L, with which 49%-80% of clinical isolates would be considered resistant
M. avium Chester
Sulfamethoxazole ureas and oxalamide [60] MIC values starting from 2 μM Several derivatives exhibited an antimycobacterial activity comparable or superior to sulfamethoxazole and isoniazid Methyl, cyclopropyl and 4-(N-(5-methylisoxazole-3-yl) sulfamoyl) phenyl were favored as the 3-ureido substituents of sulfamethoxazole-based urea
M. tuberculosis M. avium M. kansasii
Rhodanine-3-acetic acid derivatives [61] All of the derivatives were active against mycobacteria even isoniazid-resistant atypical mycobacteria M. tuberculosis M. avium M. kansasii Piperidinol derivatives [62] The piperidinyl and the bis-Mannich base analog were found to be selective for mycobacteria and rapidly kill this organism with a cytotoxicity selectivity index for mycobacteria of >30-fold
M. smegmatis
Thiosemicarbazide Derivatives [63] Most of the compounds showed good activity against the test organism
M. bovis
Fluorene Bisamide Derivatives [64] Most active compound (MIC of 1.95 μg/mL) against M. bovis M. bovis M. tuberculosis Sesamol (Ses) a natural phenolic compound [65] MIC 6mM Results indicated that Ses is involved in the disruption of the membrane integrity of Mycobacteria and also induces reactive oxygen species
to other pathogenic organisms, is limited elsewhere globally. In general clinical trials, in relation to phage therapy, have been sparse, primarily due to safety concerns relating to the sterility and purity of phages and the potential onset of toxic shock due to the bactericidal effect of phages. Furthermore, regulatory guidelines relating to their therapeutic use require clarification. [106] Diaryltriazene derivatives [67] MIC 0.03 μg/mL M. smegmatis Free and Nanoparticle Formulations of Gallium (III) meso-Tetraphenylporphyrin (Ga (NO 3 ) 3 , GaCl 3 , gallium meso-tetraphenyl porphyrin (GaTP), and gallium nanoparticles (GaNP)) [68] For M. avium and M. abscessus under iron-free conditions Ga (NO 3 ) 3 (MICs: 8 μg/mL (31 μM) and 32 μg/mL (125 μM), respectively) GaCl 3 (MICs: 8 and 16 μg/mL, respectively) GaTP inhibited the growth (1−8μg/mL and 4−8μg/mL, except the UNMC1374 strain Traphenylporphyrin alone did not inhibit the growth of NTMs in iron-free media GaTP was more effective than GaNP in inhibiting the growth Gallium salts did not inhibit the growth of either NTM under iron-rich conditions GaNP had better and more prolonged (up to 15 days) activity against NTMs growing within the THP-1 macrophage cell line GaTP and GaNP exhibited inhibitory activities via interruption of iron acquisition during intracellular and extracellular infection
M. avium M. abscessus
Streptoxamine, a benzoisoindole-deferoxamine hybrid [69] Compound, isolated from the fermentation broth of a locust-associated Streptomyces spp. showed weak antibacterial activity, 85.6 μg/mL M. smegmatis N-alkyl-2-isonicotinoylhydrazine-1-carboxamides (synthesized from isoniazid (INH) and then cyclized to N-alkyl-5-(pyridin-4-yl)-1,3,4-oxadiazole-2-amines) [70] Most active carboxamides were substituted by short n-alkyl (MICs against Mtb. of 0.5-2 μM) Cyclization did not increase activity. 2-isonicotinoylhydrazine-1-carboxamides mechanism of action described as inhibition of enoyl-ACP reductase (InhA), similar to INH, which blocks the biosynthesis of mycolic acids N-Dodecyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-2-amine was the most efficacious oxadiazole inhibiting growth of M tb (susceptible and drug-resistant) with MIC values of 4-8 μM
M. tuberculosis (sensitive, MDR and XDR) M. avium M. kansasii
Rifabutin and Hemi-synthetic Derivatives [71] Derivatives showed potential for clinical development M. abscessus Cyclophostin and Cyclipostins analogs (CyCs) [72] 26 CyCs tested, 10 were active and inhibitory activity was exclusive to mycobacteria Best candidate further tested against 26 clinical strains MICs (<2-40 µg/mL), comparable with those of most classical antimicrobials used to treat M. abscessus infections M. chelonae-abscessus clade M. marinum M. bovis BCG M. tuberculosis N-acetylated fluorophenylalanine-based aromatic amides and esters [73] The amidic derivatives showed no significant antimycobacterial properties The majority of the esters exhibited a mild antimycobacterial activity
M. tuberculosis M. avium M. kansasii
Isoniazid-based hydrazones [74] Characterization and evaluation of antibacterial, antifungal, antimycobacterial, cytotoxic and cytostatic action M. tuberculosis M. avium M. kansasii Schiff bases derived from the sulfa drug sulfadiazine and various salicylaldehydes-4-[(2-hydroxybenzylidene) amino]-N-(pyrimidin-2-yl) benzene-sulfonamides [75] M. tuberculosis and M. kansasii were inhibited within the range of 8-250 µM In conclusion, AMR in NTM organisms presents significant clinical treatment dilemmas and challenges, for a range of infections associated with NTMs. This review presents a synthesis of novel and innovative approaches, as described in Tables 2-8, in an attempt to circumvent such AMR problems. These approaches are at various stages of development, from initial concept through to licensed intervention. The challenge remains to translate these interventions from in vitro laboratory models to effective in vivo interactions. When these are realized, then we will have the opportunity of overcoming NTM AMR, to the benefit of medicine, society, and humanity. [78] In vitro study on planktonic and immobilized (agar) bacterial cultures treated with NO (250 ppm/400 ppm) for up to 10 h Antibacterial activity was noted which was independent of pH changes M. abscessus (Multi drug resistant) NO (Novoteris, USA) [79] 8 subjects completed study (2 CF, 3 non-CF bronchiectasis, 3 NTM pulmonary disease) Treatment 160 ppm gNO for 50 min, TID during 5 weekdays for 3 consecutive NTM NTM bacterial loads weeks reduced in 50% of subjects (4/8) by at least two log 10 cfu/gm sputum Complete eradication of NTM in 3/4 subjects and 1/3 had regrowth week 8 post study Preliminary results indicate well tolerated but compared to in vitro results, may require a longer regimen to achieve eradication of NTM Orphan drug QRM-003 (Qrumpharma) novel nebulized antibiotic which utilises which utilizes clofazimine as the active pharmaceutical Ingredient [80] Models used included in vitro macrophage uptake assay, in vitro antibiotic susceptibility testing, and two in vitro mouse models of NTM infection -SCID mouse infection with M. abscessus (MABSC), and Beige mouse infection with M. avium (MAC) Potent antimycobacterial activity in vitro In vivo administration significantly reduced bacterial recovery in both acute MABSC and MAC infection models Activity was significantly greater than oral administration of the clofazimine alone, despite higher clofazimine dosing via oral administration M. abscessus M. avium ALIS [81] Biofilm and in vitro rat model ALIS effectively penetrated NTM biofilms, enhanced AMK uptake into macrophages, both in vitro and in vivo, and AMK was retained within airways and lung tissue M. avium biofilms ALIS [82] A prospective, open-label, randomized study ALIS in addition to guideline-based therapy for treatment-refractory MAC lung disease achieved significantly greater culture conversion by month 6 than guideline-based therapy alone
Bronchiectasis, COPD patients with MAC LAI [83] Treatment of 5 patients (590 mg of LAI (70 mg/mL), single daily dose every day for 3 months and then every other month with clarithromycin continuous treatment) 3 patients completed treatment and did not have any respiratory exacerbation, showed negative sputum cultures for M abscessus and stabilized their spirometric functions M. abscessus LAI [84] Phase II randomized trial Addition of LAI may be an effective treatment option for NTM lung disease that is refractory to available multidrug treatment regimens [85] Zebrafish model Antimycobacterial activity observed
M. abscessus
Bedaquiline [86] MIC ranged from 0.015 to >2 ug/ml [89] In vitro broth microdilution susceptibility testing of 103 respiratory isolates MICs ≤0.008 μg/ml (90% of isolates) 102/103 isolates had MICs of ≤0.015 μg/ml MAC Bedaquiline [90] In vitro susceptibility study of 197 clinical isolates form sputum and bronchoalveolar fluid MIC50 of 0.062 and an MIC90 of 0.125 mg/L Decreased associated with mutations in mab_4384, the gene encoding the repressor of efflux pump MmpS5/MmpL5
Clofazimine [91] In vitro susceptibility study of 209 clinical and reference isolates Single-direction cross-resistance between bedaquiline-and clofazimine (Cfz)-resistant isolates was observed M. abscessus M. fortuitum M. kansasii M. avium M. intracellulare Clofazimine [92] Observational-cohort study assessed clofazimine as used for paediatric and adult CF and non-CF patients with pulmonary and extrapulmonary NTM infection (112 patients) Safe oral drug with antimycobacterial activity
MABSC MAC
Rifabutin [93] MICs 3±2 μM (3 μg/ml) Active against clarithromycin-resistant strains M. abscessus Bamboo M. abscessus subsp.
(abscessus, bolletii, massiliense) Apramycin, Framycetin (Veterinary antibiotics) [94] In vitro antibiotic susceptibility analysis Sensitivity to apramycin and framycetin noted Resistant to other veterinary antibiotics (cefovecin, ceftiofur, lincomycin, pirlimycin, and spectinomycin)
M. abscessus
Non-antibiotic medicines used commonly in CF therapy [95] In vitro analysis of clinical isolates Antimycobacterial activity with chlorphenamine, cyclizine, ibuprofen, and lansoprazole
Zafirlukast, a leukotriene receptor antagonist [96] Zafirlukast (100 μg/ml) reduced M. abscessus free and total growth in THP-1 derived macrophages by 62% and 94%, respectively and reduced interleukin-8 concentration in supernatants from infected THP-1 derived macrophages by 99% [98] In silico screening, 3D-modeling, bioactivity and pharmacological profiling identifying novel anti-buruli ulcer substances
M. ulcerans
The Pathogen Box (http://www.pathogenbox.org/) and GSK's small-molecule M. tuberculosis leads [99] 17/568 compounds identified a hit 11/17 novel compounds against M. abscessus: GW623128X (target MmpL3) GSK2200160A, GSK2200157A (target CTP synthetase/MmpL3) MMV687807 (target proton gradient) MMV688978 (target thiol-redox homeostasis) BRL-7940SA, BRL-10988SA, BRL-8903SA, BRL-10143SA, BRL-51091AM (target DHFR inhibitor) GSK1812410A (target unknown) Developed a phenotype-based fluorescence assay for rapid screening of compound libraries against M. abscessus MIC values and dose-dependent killing curves were determined using the broth microdilution
M. abscessus
The Pathogen Box from the MMV [100] Effective compounds identified using a screening assay with isolates grown in the mid-log phase followed by resazurin reduction assays Inhibition of growth of was confirmed using a dose-response experiments MMV688844 showed the best in vitro activity
The Pathogen Box from the MMV [101] High hits noted amongst TB active compounds 
Drug delivery
Silver nanoparticles (AgNPs) [102] AgNP-VAM conjugate (Silver nano particle/vancomycin conjugate) enhanced internalization of conjugate in M. smegmatis cells compared to bare AGNPs or free VAM
M. smegmatis
Anti-virulence compounds Screening of chemical compound collections [103] Dictyostelium discoideum host model Analysis of compounds which inhibited mycobacterial virulence but not growth
M. marinum
Activation of antibacterial autophagy Cyclic peptides ohmyungsamycins [104] Drosophila melanogaster-M. marinum model Activation of antibacterial autophagy via AMPK-dependent signaling and suppressing excessive inflammation was demonstrated
Bacteriophages Novel antimycobacterial phages [105] Detailed analysis a mycobacteriophage PDRPv 
